 |
MR Vol.12 No.2 indexに戻る
 |
MODERN RHEUMATOLOGY
Vol.12 No.2 |
 |
|
|
 |
|
|
Usefulness of actarit in elderly rheumatoid arthritis |
|
|
| S. Nagaoka1, M. Ohno1, Y. Ishigatsubo2 |
(1)Department of Rheumatology, Yokohama Minami
Kyosai Hospital, 500 Mutsuura-cho, Kanazawa-ku, Yokohama 236-0032,
Japan
(2)First Department of Internal Medicine, School of Medicine, Yokohama City
University, Yokohama, Japan |
| |
| Abstract |
| Abstract Many elderly patients with rheumatoid
arthritis (RA) who have decreased physiological functions due to
aging may also have symptoms of other complications. Therefore,
attention must be paid not only to the efficacy, but also to any
possible adverse reactions, when selecting disease-modifying antirheumatic
drugs (DMARDs). In this study, we examined the efficacy and safety
of actarit for elderly patients with mildly to moderately active
rheumatism. Twenty patients with elderly rheumatoid arthritis were
enrolled on a 48-week course of actarit (300 mg/day). In the overall
evaluation, 14 out of 20 patients (70%) met the criteria for a
20% improvement in the American College of Rheumatology (ACR) core
set, and seven out of 20 patients (35%) met the criteria for a
50% improvement. In the evaluation parameters, a significant improvement
was shown in the number of swollen joints, the patient's evaluation
of pain, the patient's evaluation of chronic arthritis activity,
the doctor's evaluation of chronic arthritis activity, erythrocyte
sedimentation rate, C-reactive protein (CRP), and Lansbury's activity
index after 48 weeks. A particularly remarkable improvement was
shown in tender and swollen joints in the small joint category
in elderly onset RA. No adverse reactions and no aggravation of
complications were observed in this study. From these results,
it was concluded that actarit was a safe and highly effective drug
for use with elderly patients. |
| |
| Key words |
| Key words Actarit ・ Elderly rheumatoid arthritis
・ Small joint category |
|
|
 |
|
|
